Erytech Pharma SA (ERYP.PA)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|51||2013||Chairman of the Board and Chief Executive Officer|
|41||2016||Deputy Chief Executive Officer, Director|
|2011||Deputy Chief Executive Officer - Chief Pharmacist|
|2015||Chief Financial Officer, Chief Operating Officer|
|Director of Quality Assurance and Information Systems|
- BRIEF-Erytech FY Net Loss Widens To 33.5 Million Euros
- BRIEF-Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase
- BRIEF-Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML
- BRIEF-Erytech Pharma announces pricing of global offering of 5.4 mln new ordinary shares
- BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris